Better co-ordination, UDI key to improving EU medtech framework: UK ABHI
This article was originally published in SRA
An inquiry by the UK Parliament's Science & Technology Committee (STC) into patient safety entered a new stage on 13 June with an oral evidence session focusing on the regulation of medical implants1,2.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.